Project Grant R21AA032571
Award Date 9/10/25
Completion Date 8/31/27
Dollars Obligated $390K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
- This Project Grant award of $639,177.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, will support research to investigate the role of hepatic FOXA3 in the development and progression of alcohol-associated liver disease (ALD). The University of Arizona will conduct this research project to gain a better understanding of the mechanisms underlying the pathogenesis of ALD, which is the most prevalent...
- This federal Project Grant award of $701,051 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The grant supports research to investigate the phenotypes and functions of distinct neutrophil populations in patients with severe alcohol-associated hepatitis (AH). Key objectives include: 1) Characterizing the transcriptomic profiles and functional roles of neutrophil subsets in AH using single-cell RNA sequencing; 2)...
- This $177,736 Project Grant award was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) located in Massachusetts. The project aims to investigate the role of hepatokines, predominantly hepatocyte-secreted proteins, in the pathogenesis of alcohol-associated liver disease and alcohol-associated hepatitis. Specifically, the research will explore the involvement of the...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $249,000.00 to East Tennessee State University to characterize acetaldehyde-protein adducts and their effects on lymphocyte function in alcohol-associated liver disease. The research aims to investigate how the ethanol metabolite acetaldehyde forms adducts on proteins, particularly albumin, and how this modulates the pathogenesis of...
- This federal Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs), supports research to determine the molecular mechanism by which the neutrophilic NCF1 gene and its downstream target miR-223 impact the pathogenesis of alcohol-associated liver disease (ALD). The $249,000 project, awarded to the Trustees of Indiana University, will investigate how neutrophils drive disease severity and mediate liver injury in ALD through the...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $404,250 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Tennessee Health Science Center. The grant, awarded on September 23, 2025 with an ultimate completion date of August 31, 2027, supports research to explore the role of margaric acid in alcohol-associated liver diseases (AALD). The project aims to determine if margaric acid supplementation can attenuate alcohol-induced gut and liver...
- This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) provides $440,566 to Yale University to advance the treatment of alcohol-associated liver disease (ALD). The primary objective is to uncover therapeutic targets and develop effective ALD treatments, with a focus on the methyltransferase-like (METTL) protein family, notably METTL7A, which is highly expressed in ALD patients. The research utilizes cutting-edge technology...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $550,417 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Texas at Austin. The grant, effective September 1, 2025 through May 31, 2030, supports research to investigate how heavy alcohol exposure in aging individuals leads to impaired microglia function, neurodegeneration, and cognitive deficits. The study aims to determine whether dysregulated neuroimmune and microglia responses are...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $253,383 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to explore the role of the hepatocyte inflammasome in alcoholic liver disease (ALD). This research aims to investigate the liver-specific effects of the inflammasome, a key mediator of inflammation, in hepatocytes - the predominant liver cell type and a driver of ALD pathophysiology. The project will use mouse models to evaluate...